View Mobile Friendly Conference List »

Setting new standards in information exchange for the pharmaceutical and biotech industry


R&D Leadership Speaker Dr Mene Pangalos, AstraZeneca Provides Insight into the New Apollo Therapeutics Fund

  • January 26, 2016

  • A unique collaboration between AstraZeneca, GlaxoSmithKline, Johnson & Johnson Innovation and the technology transfer offices of Imperial College London, UCL and the University of Cambridge was announced this week to build a £40 million fund to drive therapeutic innovation. The fund is called the Apollo Therapeutics Fund. We are delighted to announce that RDL Summit speaker, Dr Mene Pangalos, AstraZeneca is one of the fund’s partner and shares the following insights:Mene_Pangalos

    “We are delighted to be part of the Apollo Therapeutics Fund which brings together the complementary skills of academia and pharma. This partnership aligns with our commitment to being an integral part of the research community in the UK and takes a highly innovative approach to sharing both the risks and the rewards of applied research. I am confident that by working with scientists from world leading universities in the UK, namely Cambridge, UCL and Imperial College, we will help convert ground breaking science into important new treatments for patients.”

    For more information about the announcement, click the link below: